aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Rome Therapeutics is dedicated to developing innovative therapies for cancer and autoimmune diseases by harnessing the power of the repeatome, vast stretches of uncharted genetic material previously dismissed as "junk DNA." The company's mission is to unlock the therapeutic potential of these genetic regions to address unmet medical needs.
Rome Therapeutics has made significant strides in the biotech industry, leveraging cutting-edge research to pioneer new treatments. Their work has garnered attention for its novel approach and potential to revolutionize disease treatment. Notable investors include ARCH Venture Partners and Partners Innovation Fund.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Rome Therapeutics founded?
Rome Therapeutics was founded in 2020.
Where is Rome Therapeutics’s headquarters located?
Rome Therapeutics’s headquarters is located in Boston, MA, US.
When was Rome Therapeutics’s last funding round?
Rome Therapeutics’s most recent funding round was for $72M (USD) in September 2023.
How many employees does Rome Therapeutics have?
Rome Therapeutics has 64 employees as of Feb 5, 2024.
How much has Rome Therapeutics raised to-date?
As of July 05, 2023, Rome Therapeutics has raised a total of $199M (USD) since Sep 12, 2023.
Add Comparison
Total Raised to Date
$199M
USD
Last Update Sep 12, 2023
Last Deal Details
$72M
USD
Sep 12, 2023
Series B
Total Employees Over Time
64
As of Feb 2024
Rome Therapeutics Address
201 Brookline Avenue
Boston,
Massachusetts
02215
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts